Novartis AG ADR (NVS)vsZEN Graphene Solutions Ltd (ZTEK)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
ZTEK
ZEN Graphene Solutions Ltd
$0.43
+0.78%
HEALTHCARE · Cap: $48.29M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6000451% more annual revenue ($56.58B vs $942,880). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
ZTEK
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+89.6%
Fair Value
$6.28
Current Price
$0.43
$5.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 73.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -56.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : ZTEK
The strongest argument for ZTEK centers on Revenue Growth, Debt/Equity. Revenue growth of 73.1% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : ZTEK
The primary concerns for ZTEK are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while ZTEK is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
ZTEK is growing revenue faster at 73.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 23/100), backed by strong 23.9% margins. ZTEK offers better value entry with a 89.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →ZEN Graphene Solutions Ltd
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ZEN Graphene Solutions Ltd (ZTEK) is at the forefront of materials technology, specializing in the development and commercialization of high-purity graphene products derived from natural graphite. By leveraging proprietary extraction techniques, ZTEK aims to transform diverse sectors, including environmental remediation, energy storage, and advanced manufacturing, with its graphene-based solutions. The company's strong emphasis on sustainability, paired with ongoing research and development initiatives, positions it as a leader in the graphene technology market. As ZTEK exploits growth opportunities and drives innovation, it is poised to enhance long-term shareholder value amid a growing global demand for advanced materials.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?